|
Oct 10
|
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics
|
|
Oct 9
|
Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development
|
|
Jun 21
|
Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024
|
|
Jun 17
|
Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051
|
|
May 14
|
Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update
|
|
May 13
|
Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference
|
|
May 2
|
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
|
|
Apr 10
|
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
|
|
Mar 26
|
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
|
|
Mar 11
|
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
|
|
Mar 11
|
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers
|
|
Mar 5
|
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
|
|
Jan 10
|
Will Aprea Therapeutics (NASDAQ:APRE) Spend Its Cash Wisely?
|
|
Aug 10
|
Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations
|